Similar articles

• At the Checkpoint: Lung CD8(+) T Cells, Respiratory Viruses, and Chronic Obstructive Pulmonary Disease.

  Curtis JL. Curtis JL. Am J Respir Crit Care Med. 2016 Mar 15;193(6):600-2. doi: 10.1164/rccm.201511-2122ED. Am J Respir Crit Care Med. 2016. PMID: 26977966 Free PMC article. No abstract available.
• [Immunotherapy in lung cancer: checkpoint inhibitors].

  Wehler T, Wehler B, Stehle I. Wehler T, et al. Dtsch Med Wochenschr. 2015 Dec;140(24):1835-8. doi: 10.1055/s-0041-107770. Epub 2015 Dec 1. Dtsch Med Wochenschr. 2015. PMID: 26625234 Review. German.
• Programmed Death Ligand-1 Immunohistochemistry--A New Challenge for Pathologists: A Perspective From Members of the Pulmonary Pathology Society.

  Sholl LM, Aisner DL, Allen TC, Beasley MB, Borczuk AC, Cagle PT, Capelozzi V, Dacic S, Hariri L, Kerr KM, Lantuejoul S, Mino-Kenudson M, Raparia K, Rekhtman N, Roy-Chowdhuri S, Thunnissen E, Tsao MS, Yatabe Y; Members of Pulmonary Pathology Society. Sholl LM, et al. Arch Pathol Lab Med. 2016 Apr;140(4):341-4. doi: 10.5858/arpa.2015-0506-SA. Epub 2016 Jan 18. Arch Pathol Lab Med. 2016. PMID: 26780537
• The First Shall (Be) Last: Understanding Durable T Cell Responses in Immunotherapy.

  Thommen DS. Thommen DS. Immunity. 2019 Jan 15;50(1):6-8. doi: 10.1016/j.immuni.2018.12.029. Immunity. 2019. PMID: 30650381
• Anti-PD-1/PD-L1 Therapy for Non-Small-Cell Lung Cancer: Toward Personalized Medicine and Combination Strategies.

  Sui H, Ma N, Wang Y, Li H, Liu X, Su Y, Yang J. Sui H, et al. J Immunol Res. 2018 Aug 8;2018:6984948. doi: 10.1155/2018/6984948. eCollection 2018. J Immunol Res. 2018. PMID: 30159341 Free PMC article. Review.